Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 9pembrolizumab 8Radiotherapy, Intensity-Modulated 6Radiotherapy 5Carboplatin 5cemiplimab 4Paclitaxel 4durvalumab 3Surveys and Questionnaires 3Nivolumab 3tremelimumab 2Taxes 2Radiation 2olaparib 1niraparib 1lirilumab 1linrodostat 1fludarabine phosphate 1fludarabine 1dostarlimab 1bavituximab 1atezolizumab 1alpha-2'-deoxythioguanosine 1aldesleukin 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiotherapy, Image-Guided 1Proton Therapy 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Squamous Cell × bavituximab × Clear all
NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

University of Maryland, Baltimore

Phase 2 Active not recruiting
7 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡